findmyKOL

Louis Depalo, MD

Basic profile

Icahn School of Medicine at Mount Sinai

ORCIDNone on fileNPI↗
✓ Full record
RegionNew York, NY · NortheastSpecialtyPulmonary DiseaseFocusRespiratory
Last active 2024findmyKOL type: RegionalLatest publication2024Online presenceNot yet checkedPaymentsNone reportedNIH funding1991–1995Why? →

Louis Depalo is a Respiratory physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 28 publications with 4,254 citations (h-index 15).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
28publications

Distinct works indexed by OpenAlex.

4,254citations

Total citations across indexed works.

15h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1NIH grants · 1991–1995

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

36 East 57th Street
5th Floor
New York, NY 10022

Telephone

212-600-2000

Registry record last updated 7 Mar 2025.

View the NPPES registry record

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    44.8%
    Statin25.1%
    Atorvastatin Calcium59%Rosuvastatin Calcium41%
    Part D≥16 patients
    Calcium channel blocker9.1%
    Amlodipine Besylate71%Diltiazem 24hr Er (Cd)29%
    Part D<11 patients

    + 2 more classes in this area

  • Metabolism & gastrointestinal

    16.4%
    GLP-1 receptor agonist11.8%
    Ozempic51%Mounjaro49%
    Part D<11 patients
    H2 blocker4.7%
    Famotidine100%
    Part D<11 patients
  • Genitourinary & hormones

    13.3%
    alpha-Adrenergic Blocker9.3%
    Tamsulosin Hcl71%Alfuzosin Hcl Er29%
    Part D<11 patients
    5-alpha Reductase Inhibitor4%
    Finasteride100%
    Part D<11 patients
Where care is delivered (Part B), 202076.7% facility · 23.3% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 1991–1995 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”